Up to £210m of funding announced to partner with countries across Asia and Africa to tackle antimicrobial resistance and reduce the threat posed to the UK
Antimicrobial resistance remains of the world's most-serious public health threats
State-of-the-art laboratories, cutting-edge disease surveillance systems, and a bigger global workforce to tackle deadly antimicrobial resistance (AMR) will be backed by up to £210m of funding, the Government announced this week.
The funding – from the Government’s UK aid budget – will support the Fleming Fund’s activities to tackle AMR in countries across Asia and Africa over the next three years, helping to reduce the threat it poses to the UK and globally.
It will bolster the surveillance capacity in up to 25 countries where the threat and burden of AMR is highest – including Indonesia, Ghana, Kenya, and Papua New Guinea – with more than 250 laboratories set to be upgraded and provided with state-of-the-art equipment.
This investment includes new genome sequencing technology which will help track bacterial transmission between humans, animals, and the environment.
Antimicrobial resistance is a silent killer which poses a significant threat to people’s health around the world and in the UK
The investment will also strengthen the international health workforce by supporting 20,000 training sessions for laboratory staff, pharmacists, and hospital staff, and over 200 Fleming Fund scholarships to boost expertise in microbiology, AMR policy, and One Health – which recognises the connection between humans, animals, and the environment.
Secretary of State for Health and Social Care, Steve Barclay, said: “Antimicrobial resistance is a silent killer which poses a significant threat to people’s health around the world and in the UK.
“It’s vital it is stopped in its tracks and this record funding will allow countries most at risk to tackle it and prevent it from taking more lives across the world, ultimately making us safer at home.
“It also builds on work the Government is doing to incentivise drug companies to develop new antibiotics – a model which some G20 countries are looking to implement.”
Around 1.27 million people around the world die each year due to AMR – where bacteria have evolved so much that antibiotics and other current treatments are no longer effective against infections – with one in five of those deaths in children under five.
In 2019, AMR was found to have caused between 7,000-35,000 deaths in the UK alone.
This world-leading investment in AMR laboratories, workforce, and systems is a vital contribution to realise our vision of a world free of drug-resistant infection
UK Special Envoy on AMR, Dame Sally Davies, said: “I am proud and delighted that the UK’s Fleming Fund will continue to create real impact to tackle AMR and build pandemic preparedness on the ground across the world, using data to drive action and catalyse investment.
“This world-leading investment in AMR laboratories, workforce, and systems is a vital contribution to realise our vision of a world free of drug-resistant infection.”
The investment will deliver the second phase of the UK-India Fleming Fund partnership alongside India’s Ministry of Health and Family Welfare.
Worth up to £3m, it will accelerate collaboration on AMR surveillance across One Health sectors and help both countries to deliver on their 2030 roadmap.
As part of his visit to India, the Secretary of State will go to India’s National Centre for Disease Control, where India’s government and the Fleming Fund are joining forces to combat antimicrobial resistance.
He will also attend a showcase of innovative health technology with representatives from UK and Indian artificial intelligence and digital health firms in a bid to unleash further the tech partnership which is already transforming healthcare in both countries.